STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRBP
  4. [Form 4] Corbus Pharmaceuticals Holdings, Inc. Insider Trading Activity

Corbus Pharmaceuticals (CRBP) director granted RSUs and 12,300 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings director Rachelle Suzanne Jacques received new equity awards. On May 19, 2026, she was granted 3,800 restricted stock units that will be settled in common shares and vest 100% one year after the grant date. The filing notes her common stock holdings total 11,383 shares, including 8,600 unvested RSUs subject to prior vesting schedules. She was also granted options to purchase 12,300 shares of common stock at an exercise price of $9.15 per share, which will vest 100% on the one-year anniversary of the grant, under the company’s 2024 Equity Compensation Plan.

Positive

  • None.

Negative

  • None.
Insider Jacques Rachelle Suzanne
Role null
Type Security Shares Price Value
Grant/Award Stock options (right to buy) 12,300 $0.00 --
Grant/Award Common Stock, par value $0.0001 per share 3,800 $0.00 --
Holdings After Transaction: Stock options (right to buy) — 12,300 shares (Direct, null); Common Stock, par value $0.0001 per share — 11,383 shares (Direct, null)
Footnotes (1)
  1. On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported. The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.
RSU grant 3,800 units Restricted stock units granted May 19, 2026
Option grant size 12,300 options Stock options granted May 19, 2026
Option exercise price $9.15 per share Exercise price for 12,300 stock options
Shares after RSU grant 11,383 shares Common stock holdings following RSU grant
Previously unvested RSUs 8,600 units Unvested RSUs subject to earlier vesting schedules
restricted stock units ("RSUs") financial
"On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
vesting schedule financial
"The RSUs will vest 100% on the one-year anniversary from the date of grant."
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
2024 Equity Compensation Plan financial
"The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan."
stock options (right to buy) financial
"Stock options (right to buy)"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Jacques Rachelle Suzanne
(Last)(First)(Middle)
C/O CORBUS PHARMACEUTICALS HOLDINGS, INC
500 RIVER RIDGE DRIVE
(Street)
NORWOOD MASSACHUSETTS 02062
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, par value $0.0001 per share05/19/2026A3,800(1)A$011,383(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock options (right to buy)$9.1505/19/2026A12,300 (3)05/19/2026Common Stock12,300$012,300D
Explanation of Responses:
1. On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.
2. This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported.
3. The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.
/s/ Meghan Houghton, attorney-in-fact for Rachelle Jacques05/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Corbus (CRBP) director Rachelle Suzanne Jacques receive?

She received 3,800 restricted stock units and stock options for 12,300 shares. The RSUs and options both vest 100% one year after the May 19, 2026 grant date, reflecting routine director equity compensation.

How do the new RSUs for Corbus (CRBP) director vest?

The 3,800 restricted stock units vest 100% on the one-year anniversary of the May 19, 2026 grant. Once vested, they will be settled in shares of Corbus common stock, adding to the director’s equity ownership.

What are the terms of the new Corbus (CRBP) stock options granted to the director?

The director was granted options for 12,300 shares of common stock at an exercise price of $9.15 per share. These options will vest 100% on the one-year anniversary of the May 19, 2026 grant under the 2024 Equity Compensation Plan.

How many Corbus (CRBP) shares does the director hold after these awards?

After the RSU grant, the director’s reported common stock holdings total 11,383 shares. This amount includes 8,600 unvested restricted stock units that remain subject to their respective vesting schedules as previously disclosed.

Are the Corbus (CRBP) director’s new awards open-market purchases or compensation?

The Form 4 identifies both the RSU and option grants as awards, not open-market purchases. They were granted as part of the company’s compensation arrangements, including the 2024 Equity Compensation Plan, with no reported cash purchase by the director.

What plan governs the new Corbus (CRBP) stock option grant to the director?

The stock option award was made under Corbus Pharmaceuticals’ 2024 Equity Compensation Plan. The footnote states that the option will vest 100% on the one-year anniversary of the grant date, consistent with the plan’s terms for this award.